1 edition of effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia found in the catalog.
effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia
Includes bibliographical references.
|Statement||R. Garside ... [et al.].|
|Series||Health technology assessment -- v.6, no.33|
|Contributions||Garside, R., National Co-ordinating Centre for HTA (Great Britain), Health Technology Assessment Programme.|
|The Physical Object|
|Pagination||vi,162 p. :|
|Number of Pages||162|
Hydroxycarbamide, also known as hydroxyurea, is a medication used in sickle-cell disease, chronic myelogenous leukemia, cervical cancer, and polycythemia vera. In sickle-cell disease it increases fetal hemoglobin and decreases the number of attacks. It is taken by mouth. Common side effects include bone marrow suppression, fevers, loss of appetite, psychiatric problems, Metabolism: liver (to CO2 and urea). Objectives To examine contemporary survival patterns in the general population of patients diagnosed with chronic myeloid leukaemia (CML), and to identify patient groups with less than optimal outcomes. Design Prospective population-based cohort. Setting The UK's Haematological Malignancy Research Network (catchment population million, with > Cited by:
INTRODUCTION. Over the past 15 years, cancer drug prices have risen drastically. The average price of a cancer drug was $ to $10, before and increased to more than $, in 1, 2 In that year, 12 of the 13 drugs approved by the Food and Drug Administration for cancer indications were priced higher than $, In , almost every new cancer drug Cited by: The book This section of the contains the online version of Evans I, Thornton H, Chalmers I and Glasziou P (). Testing Treatments, 2nd Edition; London: Pinter and Martin.
Simonsson B, Conti RM. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States. J Natl Cancer Inst. Mar 4;(7). pii: djw doi: /jnci/djw Miranda MB, Lauseker M, Kraus MP, Proetel U, Hanfstein B, Fabarius A,File Size: KB. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. ; – doi: /JCO [Google Scholar] Thompson Healthcare. Red Book: Pharmacy’s Fundamental Reference.
Twenty Years of Statutory Redundancy Payments in Great Britain . . . (Occasional Papers in Industrial Relations / Universities of)
manual of the ornithology of the United States and of Canada.
Proximate chemical composition and fatty acid contents of 37 finfish species of the southeastern United States
Levels and sources of forest fire prevention knowledge of California hunters
The effect of the covariance factor on the Procurement Problem Variance of net leadtime demand
Painting, photography, film.
Science and the social order
RACER # 3338949
How to avoid unnecessary surgery
natural rate hypothesis, policy rules, and fixed exchange rates
Governing bodies of sport
Culinary arts and sciences
The effectiveness and cost-effectiveness of imatinib in chronic myeloid leukaemia: A systematic review February Health technology assessment (Winchester, England) 6(33) Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia Article (PDF Available) in PLoS ONE 14(12):e December with 40 Reads.
Model structure. The model was a Markov cost-effectiveness model, written in Microsoft Excel. It assumed that patients start second-line treatment aged 57 years, with a 50 male – female ratio, consistent with the main Phase II study of nilotinib in AP. Patients were modelled until age years, implying a lifetime horizon of 43 years.
The model cycle length was 3 : G Rogers, M Hoyle, J Thompson Coon, T Moxham, Z Liu, M Pitt, K Stein. Introduction.
Chronic myeloid leukemia (CML) is the third most common type of leukemia .Init is estimated that 5, people will be diagnosed and people will die from CML in the United States (US) .The disease course consists of three phases .Although there are some differences in the clinical and pathological definitions of these phases, the progression from Cited by: 9.
The cost-effectiveness analysis based on the incremental cost-effectiveness ratio (ICER) showed that imatinib first is the most cost-effective approach. None of the other 3 strategies met a WTP threshold based on ICER ($ in the United States [US dollars] and ¥7 in Japan [Japanese yen] per QALY), in comparison with imatinib by: 1.
The effectiveness and cost-effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase, 28 March B The following organisations accepted the invitation to participate in this appraisal.
They were invited to make submissions and comment on the draft scope, Assessment Report and the Appraisal Consultation. Imatinib for chronic myeloid leukaemia.
Impressive results have also been seen in patients given imatinib for chronic myeloid leukaemia , .Before imatinib was introduced in the late s, this type of leukaemia responded very poorly to standard treatments. Chronic phase (after failure of or intolerance to IFN-α) In the case series that investigated the efficacy of imatinib in people with late chronic-phase CML, for whom previous therapy with IFN-α had failed, complete HR was achieved in 95% of people, major CR (complete or partial) in 60% of people, and complete CR in 41% of people, at 18 months.
Currently several tyrosine kinase inhibitors (TKIs) are approved for treatment of chronic myeloid leukemia (CML).
Our goal was to identify the optimal sequential treatment strategy in terms of effectiveness and cost-effectiveness for CML patients within the US health care context. We evaluated 18 treatment strategies regarding survival, quality-adjusted survival, and by: 9. Dalziel K, Round A, Stein K, Garside R, et al.
The effectiveness and cost effectiveness of imatinib for first line treatment of chronic myeloid leukaemia in chronic phase. Monograph London: National Institute for Clinical Excellence, Oct Google ScholarCited by: For each scenario, we examined the impact of the combination of health utilities for chronic-phase chronic myeloid leukaemia (base case 089, range 0–1) and the annual cost of second-generation TKIs (base case US$ [ie, the price of nilotinib in the USA], range 0– ) on the cost-effectiveness of second-generation TKIs compared Cited by: 7.
We used month survival data from the IRIS (International Randomized study of Interferon vs STI) trial to update previously published cost-effectiveness estimates, based on 19 months of follow-up, of imatinib versus interferon (IFN)-ag plus low-dose cytarabine in patients with chronic-phase chronic myeloid by: Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: a modelling study Author: A.
Hochhaus, M. Baccarani, R. Silver, C. Schiffer, J. Apperley, F. Cervantes, R. Clark, J. Imatinib is recommended as first-line treatment for people with Philadelphia-chromosome-positive chronic myeloid leukaemia (CML) in the chronic phase. Imatinib is recommended as an option for the treatment of people with Philadelphia-chromosome-positive CML who initially present in the accelerated phase or with blast crisis.
In his book, Daniel Vasella, then Chairman and Chief Executive Officer of Novartis, discussed the development of imatinib, the moral imperatives and pressures exerted by oncologists and patients, the need for healthy profit margins, and the decision to price imatinib at a world average of $ per month, or $26 per year ($30 per year.
Introduction. Prevalence of chronic myeloid leukaemia (CML) is about 10–12 perpeople worldwide, with an estimated incidence rate in the United States of America (USA) of cases in CML is a clonal haematopoietic stem cell disorder with an abnormal expression of the oncoprotein BCR-ABL1, which is a constitutively active tyrosine kinase.Cited by: 4.
Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess. ; 8(28): iii, The cost of TKIs was based on the wholesale acquisition cost in the RED BOOK 3 and that of office visit for monitoring purposes was from Medicare Physician Fee Schedule.
27 For the base-case health utility for patients with chronic-phase chronic myeloid leukaemia responding to therapy, we used the value of 089 in the USA, taken from a Cited by: 7. Evidence-based recommendations on imatinib for people with chronic myeloid leukaemia.
Is this guidance up to date. We reviewed the evidence in October We found nothing new that affects the recommendations in this guidance. Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations. Dalziel K., Round A., Garside R., Stein K.
Cost effectiveness of imatinib compared with interferon-α or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. ; 23 (5)– doi: /Cited by: 9.
Micro-AbstractTyrosine-kinase inhibitor (TKI) treatment of chronic myeloid leukemia (CML) can be associated with vascular events (VEs). We examined the event rates and mortality among elderly patients with and without CML using linked cancer registry and Medicare claims data from to The patients with CML had greater mortality and VE by: treatment-free remission in patients with chronic myeloid leukaemia: a modelling study Ya-Chen Tina Shih, Jorge E Cortes, Hagop M Kantarjian the price of nilotinib in the USA], range 0– ) on the cost-effectiveness of second-generation TKIs compared with generic imatinib.
We used different price scenarios for RED BOOK, 3 the. Purpose A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI).
We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a result of CML between and in Sweden. Materials and Cited by: